Avalia Immunotherapies collapses, owes $1m to Callaghan Innovation

Avalia Immunotherapies collapses, owes $1m to Callaghan Innovation
Dr Shivali Gulab, CEO of Avalia Immunotherapies. (Image: Avalia)
Riley Kennedy
Liquidators have been appointed to a biotech outfit that helped produce a covid-19 vaccine after it failed to raise cash to help further its other project.Founded in 2015, Avalia Immunotherapies was a preclinical-stage biotech company attempting to develop a fully synthetic vaccine and immunotherapy platform. Its lead programme was targeting a functional cure for chronic Hepatitis B.After it couldn’t raise further funding for clinical development, Baker Tilly Staples Rodway’s Tony Maginness and Jared Booth were appointed liquid...

More Finance

Co-operative Bank, ComCom agree penalty fee
Finance

Co-operative Bank, ComCom agree penalty fee

The bank is silent on the penalty amount it and the Commerce Commission are aligned on.

RBNZ reopens Wellington office after asbestos mayhem
Finance

RBNZ reopens Wellington office after asbestos mayhem

Bank tight-lipped on how many staff are home-working as asbestos-hit office reopens. 

Andy Macdonald 21 Nov 2025
Big banks eye warnings on legacy Open Banking technology
Finance

Big banks eye warnings on legacy Open Banking technology

Their interest comes with dawn of API-led Open Banking just weeks away. 

Andy Macdonald 19 Nov 2025
Banks accelerate crackdown on ‘mule’ scammers
Finance

Banks accelerate crackdown on ‘mule’ scammers

New technology picks up crooked “muleteers” more quickly.

Andy Macdonald 17 Nov 2025